<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470390</url>
  </required_header>
  <id_info>
    <org_study_id>LAZA-PK-401</org_study_id>
    <nct_id>NCT02470390</nct_id>
  </id_info>
  <brief_title>Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl</brief_title>
  <official_title>An Open-Label Single-Dose Crossover Study Comparing the Plasma and Cerebrospinal Fluid Pharmacokinetics and Bioavailability of Fentanyl Delivered Intranasally Versus Sublingually Versus Intravenously in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Depomed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A partially randomized, open-label, 3-way crossover, single-center, systemic and CSF PK and
      bioavailability study in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label Single-Dose Crossover Study Comparing the Plasma and Cerebrospinal Fluid
      Pharmacokinetics and Bioavailability of Fentanyl Delivered Intranasally Versus Sublingually
      Versus Intravenously in Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Cerebrospinal Fluid (CSF) (1 of 3)</measure>
    <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Fentanyl in Cerebrospinal Fluid (CSF) (2 of 3)</measure>
    <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Hour 0 to Hour 6 (AUC 0-6h) of Fentanyl in Cerebrospinal Fluid (CSF) (3 of 3)</measure>
    <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Fentanyl in Plasma (1 of 5)</measure>
    <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
    <description>Cmax (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUC 0-tlast) of Fentanyl in Plasma (2 of 5)</measure>
    <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
    <description>AUC 0-tlast (pg*h/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) of Fentanyl in Plasma (3 of 5)</measure>
    <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
    <description>AUC 0-inf (pg*h/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Plasma (4 of 5)</measure>
    <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
    <description>Tmax (h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of Fentanyl in Plasma (5 of 5)</measure>
    <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
    <description>t1/2 (h)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nasal fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.
Will be administered on either study day 1 or 3 per protocol and randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Lingual fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.
Will be administered on either study day 1 or 3 per protocol and randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.
Will be administered on study day 5 per protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl</description>
    <arm_group_label>Nasal fentanyl</arm_group_label>
    <arm_group_label>Sub-Lingual fentanyl</arm_group_label>
    <arm_group_label>IV fentanyl</arm_group_label>
    <other_name>Lazanda, Subsys, IV fentanyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal healthy male or female between the ages of 18 to 65 years. Never smokers or
             Non-smokers (cessation of smoking ≥ 6 months ago). Body Mass Index (BMI =
             weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 32.0
             kg/m2.

        No clinically meaningful findings in the physical examination, oral and nasal examination
        and 12-lead electrocardiogram.

        Negative for drugs of abuse, alcohol, and nicotine. Negative for hepatitis A, B, and C and
        Human Immunodeficiency Virus (HIV). No clinical laboratory values outside of the acceptable
        range, unless, in the opinion of the Principal Investigator, they are deemed not clinically
        significant.

        Exclusion Criteria:

          -  Subject has a known history of allergic reaction, hypersensitivity, or clinically
             significant intolerance to opioids, fentanyl or components of the study drugs.

             2. Subjects with a high potential for opioid addiction (personal or family history).

             3. Subject is lactating or considered at risk of pregnancy. 4. Subject has impaired
             liver function (e.g., alanine aminotransferase [ALT] ≥ 3 times the upper limit of
             normal [ULN] or bilirubin ≥ 3 times ULN), known active hepatic disease (e.g.,
             hepatitis), or evidence of clinically significant liver disease or other condition
             affecting the liver that may suggest the potential for an increased susceptibility to
             hepatic toxicity with oral diclofenac exposure.

             5. Subject has any history of renal disease that, in the opinion of the investigator,
             would contraindicate study participation; or subject has significantly impaired renal
             function as evidenced by an estimated GFR of ≤60 ml/min/1.73m2.

             6. Subject has a history or evidence of significant nasal pathology, including polyps
             or nasal obstructions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of R&amp;D</last_name>
    <role>Study Director</role>
    <affiliation>Depomed</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>March 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2018</results_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <keyword>Pharmacokenetics (PK) (plasma and Cerebrospinal Fluid [CSF])</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 13 healthy subjects were randomly assigned to treatment in this crossover study: 6 in the &quot;Nasal Fentanyl First, then Sublingual Fentanyl and IV Fentanyl&quot; arm and 7 in the &quot;Sublingual Fentanyl First, then Nasal Fentanyl and IV Fentanyl&quot; arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nasal Fentanyl First, Then Sublingual Fentanyl and IV Fentanyl</title>
          <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 per protocol.
Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 3 per protocol.
IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
        </group>
        <group group_id="P2">
          <title>Sublingual Fentanyl First, Then Nasal Fentanyl and IV Fentanyl</title>
          <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 per protocol.
Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 3 per protocol.
IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nasal Fentanyl First, Then Sublingual Fentanyl and IV Fentanyl</title>
          <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 per protocol.
Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 3 per protocol.
IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
        </group>
        <group group_id="B2">
          <title>Sublingual Fentanyl First, Then Nasal Fentanyl and IV Fentanyl</title>
          <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 per protocol.
Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 3 per protocol.
IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="14.38"/>
                    <measurement group_id="B2" value="43.0" spread="9.50"/>
                    <measurement group_id="B3" value="41.2" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Cerebrospinal Fluid (CSF) (1 of 3)</title>
        <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
        <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Cerebrospinal Fluid (CSF) (1 of 3)</title>
          <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.75" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.75" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Fentanyl in Cerebrospinal Fluid (CSF) (2 of 3)</title>
        <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
        <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Fentanyl in Cerebrospinal Fluid (CSF) (2 of 3)</title>
          <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.54" spread="47.10"/>
                    <measurement group_id="O2" value="56.37" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Hour 0 to Hour 6 (AUC 0-6h) of Fentanyl in Cerebrospinal Fluid (CSF) (3 of 3)</title>
        <time_frame>6 hrs (pre-dose, 5, 10, 20, 30, 45, &amp; 60 min, and 2, 3, 4, &amp; 6 hrs post-dose on Study Days 1 &amp; 3)</time_frame>
        <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Hour 0 to Hour 6 (AUC 0-6h) of Fentanyl in Cerebrospinal Fluid (CSF) (3 of 3)</title>
          <population>The CSF PK population included all subjects who completed all study periods and Cmax was less than 5% pre-dose. The above CSF PK outcome compares nasal and sublingual fentanyl interventions.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.25" spread="121.93"/>
                    <measurement group_id="O2" value="221.49" spread="76.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Fentanyl in Plasma (1 of 5)</title>
        <description>Cmax (pg/mL)</description>
        <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
        <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O3">
            <title>IV Fentanyl</title>
            <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Fentanyl in Plasma (1 of 5)</title>
          <description>Cmax (pg/mL)</description>
          <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541.28" spread="78.1"/>
                    <measurement group_id="O2" value="369.59" spread="41.4"/>
                    <measurement group_id="O3" value="1166.51" spread="130.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUC 0-tlast) of Fentanyl in Plasma (2 of 5)</title>
        <description>AUC 0-tlast (pg*h/mL)</description>
        <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
        <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O3">
            <title>IV Fentanyl</title>
            <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUC 0-tlast) of Fentanyl in Plasma (2 of 5)</title>
          <description>AUC 0-tlast (pg*h/mL)</description>
          <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2752.51" spread="37.3"/>
                    <measurement group_id="O2" value="2359.08" spread="27.5"/>
                    <measurement group_id="O3" value="2236.46" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) of Fentanyl in Plasma (3 of 5)</title>
        <description>AUC 0-inf (pg*h/mL)</description>
        <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
        <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter. The AUC 0-inf values were excluded where %AUC extrap was greater than 20%.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O3">
            <title>IV Fentanyl</title>
            <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) of Fentanyl in Plasma (3 of 5)</title>
          <description>AUC 0-inf (pg*h/mL)</description>
          <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter. The AUC 0-inf values were excluded where %AUC extrap was greater than 20%.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3413.80" spread="34.8"/>
                    <measurement group_id="O2" value="2879.85" spread="26.0"/>
                    <measurement group_id="O3" value="2871.89" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Plasma (4 of 5)</title>
        <description>Tmax (h)</description>
        <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
        <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O3">
            <title>IV Fentanyl</title>
            <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Plasma (4 of 5)</title>
          <description>Tmax (h)</description>
          <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.17" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.03" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-Life (t1/2) of Fentanyl in Plasma (5 of 5)</title>
        <description>t1/2 (h)</description>
        <time_frame>24 hrs (pre-dose, 5, 10, 15, 20, 30, 45, &amp; 60 min, and 1.5, 2, 3, 4, 6, 8, 12, &amp; 24 hrs on Study Days 1 &amp; 3 for Nasal Fentanyl / Sublingual Fentanyl; pre-dose, 2, 5, 10, 20, 30, &amp; 60 min, and 2, 4, 6, 8, 12, &amp; 24 hrs on Study Day 5 for IV Fentanyl)</time_frame>
        <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Fentanyl</title>
            <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Fentanyl</title>
            <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
          </group>
          <group group_id="O3">
            <title>IV Fentanyl</title>
            <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2) of Fentanyl in Plasma (5 of 5)</title>
          <description>t1/2 (h)</description>
          <population>The Plasma PK population included all subjects who received at least 1 dose of study drug and had at least 1 evaluable PK parameter.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="40.0"/>
                    <measurement group_id="O2" value="10.73" spread="39.6"/>
                    <measurement group_id="O3" value="12.25" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Adverse Events were reported from the signed informed consent to 30 days after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nasal Fentanyl</title>
          <description>Nasal Fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute on Study Day 1 or 3 per protocol.</description>
        </group>
        <group group_id="E2">
          <title>Sublingual Fentanyl</title>
          <description>Sublingual Fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue on Study Day 1 or 3 per protocol.</description>
        </group>
        <group group_id="E3">
          <title>IV Fentanyl</title>
          <description>IV Fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes on Study Day 5 per protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Radicular Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Depomed</organization>
      <phone>510-744-8000</phone>
      <email>clinicaltrials@depomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

